N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action

Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2003, Pages 1546-1553

  Lagoja, Irene M ^a   Pannecouque, Christophe ^a   Van Aerschot, Arthur ^a   Witvrouw, Myriam ^a   Debyser, Zeger ^a   Balzarini, Jan ^a   Herdewijn, Piet ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; IMIDAZOLE DERIVATIVE; N AMINOIMIDAZOLE DERIVATIVE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOUSE; NONHUMAN; RETROVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMIDAZOLES; MICE; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 0242500883     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0211117     Document Type: Article

References (27)

1. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
2. (a) Coffin, J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267, 483-489.
3. (b) Vandamme, A.-M.; Van Vaerenbergh, K.; De Clercq, E. Anti-human immunodeficiency virus drug combination strategies. Antiviral Chem. Chemother. 1998, 9, 187-203.
4. Richman, D. D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S. A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D.; Shih, C.-K.; Myers, M.; Griffin, J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68, 1660-1666.
5. Fujiwara, T.; Sato, A.; El-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42, 1340-1345.
6. Ren, J.; Nichols, C.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D. I.; Stammers, D. K. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 2000, 275, 14316-14320.
7. Schantl, J. G.; Lagoja, I. Direct synthetic approach to N-substituted 1-amino-2,3-dihydro-1H-imidazole-2-thiones. Heterocycles 1997, 45, 691-700.
8. Sitte, A.; Wessel, R.; Paul, H. Umwandlung von 1,3,4-Thiadiazolinen in 1,2,4-Triazole durch Dimroth-Umlagerung. Monatsh. Chem. 1975, 106, 1291-1296.
9. Schantl, J. G.; Lagoja, I. M. Oxidative Reduction of Cyclic Thiosemicarbazides: Conversion of 1-Arylamino-2,3-dihydro-1-Himidazole-2-thiones into 1-Arylamino-1H-imidazoles. Heterocycles 1998, 48 (5), 929-938.
10. Dodd, D. S.; Kozikowski, Conversion of Alcohols to Protected Guanidines Using the Mitsunobu Protocol. Tetrahedron Lett. 1994, 35 (7), 977-980.
11. (a) Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
12. (b) Pluymers, W.; Pais, G.; Van Maele, B.; Pannecouque, C.; Fikkert, V.; Burke, T.; De Clereq, E.; Witvrouw, M.; Neamati, N.; Debyser, Z. Inhibition of HIV-1 integrase activity and replication by a series of diketo derivatives. Antimicrob. Agents Chemother., submitted.
13. Horwitz, J. P.; Chua, J.; Noel, M. Nucleoside V, the monomesylates of 1-(2′-deoxy-β-D-lyxyfuranosyl)thymine. J. Org. Chem. 1964, 29, 2076.
14. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, Isolation and Continuous Production of Cytopathic Retroviruses (HTLV-III) from patients with AIDS or pre-AIDS. Science 1984, 224, 497-500.
15. Adachi, A.; Gendelman, H.; Koenig, S.; Folks, T.; Willey, R.; Rabson, A.; Martin, M. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59, 284-291.
16. Barré-Sinoussi, F.; Chermann, J. C.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for AIDS. Science 1983, 220, 868-871.
17. Daniel, M. D.; Letvin, N. L.; Sehgal, P. K.; Hunsmann, G.; Schmidt, D. K.; King, N. W.; Desrosiers, R. C. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J. Gen. Virol. 1987, 68, 3183-3189.
18. Harada, S.; Koyanagi, Y.; Yamamoto, N. Infection of HTLV-III/LAV in HTLV-I carrying cells MT-2 and MT-4: an application in a plaque assay. Science 1985, 229, 563-566.
19. De Clercq, E.; Merigan, T. C. Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (polyrI):poly(rC). Proc. Soc. Exp. Biol. Med. 1971, 137, 590-594.
20. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and Automated Tetrazolium-Based Colorimetric Assay for Detection of anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.
21. Japour, A. J.; Mayers, D. L.; Johnson, V. A.; Kuritzkes, D. R.; Beckett, L. A.; Arduino, J. M.; Lane, J.; Black, R. J.; Reichelderfer, P. S.; D'Aquila, R. T.; Crumpacker, C. S. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. 1993, 37, 1095-1101.
22. Balzarini, J.; Holý, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; De Clercq, E. Differential antiherpesvrius and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-52-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 1993, 37, 332-338.
23. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J. Potent and selective inhibition of HIV-1 replication by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
24. (a) Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.-J.; Vrang, L.; Walbers, J.; Zhang, H.; Öberg, B.; Vandamme, A.-M.; Camarasa, M.-J.; De Clercq, E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acids substitutions in the reverse transcriptase. Virology 1993, 192, 246-253.
25. (b) Balzarini, J.; Karlsson, A.; De Clercq, E. Human immunodeficiency virus type 1 drug resistance patterns with different 1-(2-hydroxyethoxy)methyl-6-(phenylthio)thymine derivatives. Mol. Pharmacol. 1993, 44, 694-701.
26. (a) Cherepanov, P.; Esté, J. A.; Rando, R. F.; Ojwang, J. O.; Reekmans, G.; Steinfeld, R.; David, G.; De Clercq, E.; Debyser, Z. Mode of action of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 1997, 52, 771-780.
27. (b) Debyser, Z.; Cherepanov, P.; Pluymers, W.; De Clercq, E. Assays for the evaluation of HIV-1 integrase inhibitors. In Methods in Molecular Biology. Nucleases. Humana Press: Clifton, NJ, 2001.